Nautilus Biotechnology annual current ratio
2020
2021
2022
2023
2024
2025
Nautilus Biotechnology Current Ratio Growth & History (NAUT)
Nautilus Biotechnology's current ratio was 13.33 for fiscal 2025.
View full Nautilus Biotechnology company overviewNautilus Biotechnology annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 13.33 | −4.08 | −23.43% |
| 2024 | 2024-12-31 | 17.40 | −1.98 | −10.22% |
| 2023 | 2023-12-31 | 19.39 | −8.18 | −29.68% |
| 2022 | 2022-12-31 | 27.57 | −32.52 | −54.12% |
| 2021 | 2021-12-31 | 60.09 | 34.35 | +133.51% |
| 2020 | 2020-12-31 | 25.73 | — | — |
Nautilus Biotechnology quarterly current ratio
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 10.14 | −8.38 | −45.24% |
| Q1 2026 | 2026-03-31 | 11.85 | −5.52 | −31.77% |
| Q4 2025 | 2025-12-31 | 13.33 | −4.08 | −23.43% |
| Q3 2025 | 2025-09-30 | 14.95 | −1.69 | −10.17% |
| Q2 2025 | 2025-06-30 | 18.52 | −1.17 | −5.93% |
| Q1 2025 | 2025-03-31 | 17.36 | −2.73 | −13.59% |
| Q4 2024 | 2024-12-31 | 17.40 | −1.98 | −10.22% |
| Q3 2024 | 2024-09-30 | 16.65 | −4.35 | −20.73% |
| Q2 2024 | 2024-06-30 | 19.69 | −1.44 | −6.81% |
| Q1 2024 | 2024-03-31 | 20.09 | −1.41 | −6.55% |
| Q4 2023 | 2023-12-31 | 19.39 | −8.18 | −29.68% |
| Q3 2023 | 2023-09-30 | 21.00 | −19.60 | −48.27% |
| Q2 2023 | 2023-06-30 | 21.13 | −28.63 | −57.53% |
| Q1 2023 | 2023-03-31 | 21.50 | −29.55 | −57.89% |
| Q4 2022 | 2022-12-31 | 27.57 | −32.52 | −54.12% |
| Q3 2022 | 2022-09-30 | 40.60 | −43.08 | −51.48% |
| Q2 2022 | 2022-06-30 | 49.75 | −66.19 | −57.09% |
| Q1 2022 | 2022-03-31 | 51.06 | — | — |
| Q4 2021 | 2021-12-31 | 60.09 | 34.35 | +133.51% |
| Q3 2021 | 2021-09-30 | 83.68 | — | — |
| Q2 2021 | 2021-06-30 | 115.95 | — | — |
| Q4 2020 | 2020-12-31 | 25.73 | — | — |
Nautilus Biotechnology current ratio trends
Over the last five fiscal years, Nautilus Biotechnology's current ratio decreased from 25.73 to 13.33, a change of −12.41. The latest reported quarter, Q2 2026, shows 10.14.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nautilus Biotechnology source filings ↗